Summary:
- This article discusses a lawsuit filed against Columbia University trustee Mark Shendelman, alleging that he used his position to influence pharmaceutical company decisions and profit from insider information.
- The lawsuit claims Shendelman leveraged his role on Columbia's board to gain access to confidential information about a pharmaceutical company's drug trials, which he then used to make lucrative stock trades.
- The case highlights concerns about potential conflicts of interest and the need for stronger oversight and transparency in the relationships between academic institutions, their leadership, and the pharmaceutical industry.